AbbVie's Allergan Aesthetics Reinforces Scientific Leadership With 21 Evidence-Based E-Posters Across Full Aesthetics Portfolio At AMWC 2026

AbbVie's Allergan Aesthetics showcased 21 evidence-based e-posters at AMWC 2026, emphasizing their scientific leadership in the aesthetics sector. Notably, five e-posters focused on the investigational neurotoxin trenibotulinumtoxinE (TrenibotE), which showed rapid improvement in glabellar lines and a favorable safety profile. Additionally, data supporting onabotulinumtoxinA (BOTOX® Cosmetic) highlighted its role in achieving high patient satisfaction and natural results, reinforcing AbbVie's commitment to innovative aesthetic treatments.